Interpace Biosciences, Inc. (IDXG)
OTCMKTS · Delayed Price · Currency is USD
0.8600
-0.0610 (-6.62%)
Nov 20, 2025, 11:12 AM EST
Interpace Biosciences Employees
Interpace Biosciences had 111 employees as of December 31, 2024. The number of employees increased by 3 or 2.78% compared to the previous year.
Employees
111
Change (1Y)
3
Growth (1Y)
2.78%
Revenue / Employee
$377,613
Profits / Employee
$30,045
Market Cap
3.81M
Employees Chart
Employees History
| Date | Employees | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | 111 | 3 | 2.78% |
| Dec 31, 2023 | 108 | 14 | 14.89% |
| Dec 31, 2022 | 94 | -53 | -36.05% |
| Dec 31, 2021 | 147 | -5 | -3.29% |
| Dec 31, 2020 | 152 | -26 | -14.61% |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2015 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Related Stocks
| Company Name | Employees |
|---|---|
| American Oncology Network | 1,914 |
| Glass House Brands | 374 |
| Silence Therapeutics | 116 |
| Elite Pharmaceuticals | 68 |
| Northwest Biotherapeutics | 25 |
| CytoDyn | 13 |
| Tian'an Technology Group | 8 |
Interpace Biosciences News
- 10 days ago - Interpace Biosciences Announces Third Quarter 2025 Financial and Business Results - GlobeNewsWire
- 2 months ago - Interpace Biosciences (IDXG) Showcases Promising Thyroid Nodule Testing Advances - GuruFocus
- 2 months ago - Interpace Biosciences Presented Two New Posters at the 2025 American Thyroid Association® (ATA) Annual Meeting - GlobeNewsWire
- 7 months ago - Effective May 2, 2025, Interpace Diagnostics® Will No Longer Accept Specimens for PancraGEN®, a Molecular Diagnostic Test That Assesses Pancreatic Cyst Cancer Risk - GlobeNewsWire
- 10 months ago - Interpace Biosciences Announces Preliminary Full-year and Fourth Quarter 2024 Financial and Business Results - GlobeNewsWire
- 10 months ago - PancraGEN® Will Continue to be Offered While Interpace Re-evaluates its Previously Announced Re-structuring Plan - GlobeNewsWire
- 11 months ago - Effective 02/07/2025, Interpace Diagnostics® to No Longer Offer PancraGEN®, a Molecular Diagnostic Test That Assesses Pancreatic Cyst Cancer Risk - GlobeNewsWire
- 1 year ago - Interpace Biosciences Announces Record Third Quarter 2024 Financial and Business Results - GlobeNewsWire